Legal Opinion
New York v. Amgen Inc.
Court of Appeals for the First Circuit
Decided July 22, 2011No. 10-1629, 10-1630, 10-1633, 10-1634, 10-1635, 10-1636, 10-1954, 10-1955PublishedCited by 39 opinions
1Opinion of the Court
LYNCH, Chief Judge.
Relator Kassie Westmoreland and the plaintiff state intervenors in this qui tarn action appeal from a Rule 12(b)(6) dismissal of their pendent state False Claims Act (FCA) causes of action against Amgen, Inc. (Amgen), International Nephrology Network (INN), and ASD Healthcare (ASD). The district court exercised jurisdiction over the action, which also alleged violations of the federal FCA, 31 U.S.C. § 3729 et seq., pursuant to 31 U.S.C. § 3732(b), 28 U.S.C. § 1331, and 28 U.S.C. § 1367. We have jurisdiction over this appeal concerning only questions of state law pursuant to…
2Cases cited14 opinions
- Alexander v. ChoateSupreme Court of the United States · 1985
- Gagliardi v. SullivanCourt of Appeals for the First Circuit · 2008
- Pharmaceutical Research and Manufacturers of America v. Walsh, Acting Commissioner, Maine Department of Human ServicesSupreme Court of the United States · 2003
- United States Ex Rel. Hutcheson v. Blackstone Medical, Inc.Court of Appeals for the First Circuit · 2011
- United States of America, Ex Rel. Mary Hendow Julie Albertson v. University of PhoenixCourt of Appeals for the Ninth Circuit · 2006
9 more not listed; retrieve them via the Exa API.
3Cited by39 opinions
- Guilfoile v. ShieldsCourt of Appeals for the First Circuit · 2019
- United States Ex Rel. Grenadyor v. Ukrainian Village Pharmacy, Inc.Court of Appeals for the Seventh Circuit · 2014
- Feliciano-Hernandez v. Pereira-CastilloCourt of Appeals for the First Circuit · 2011
- United States ex rel. Kester v. Novartis Pharmaceuticals Corp.District Court, S.D. New York · 2014
- Eves v. LePageCourt of Appeals for the First Circuit · 2019
34 more not listed; retrieve them via the Exa API.